期刊文献+

不同类型淋巴瘤患者肿瘤坏死因子-β的表达及其临床意义 被引量:2

Expression of TNF-β in subtypes of lymphoma and its significance
下载PDF
导出
摘要 目的探讨不同类型淋巴瘤患者肿瘤坏死因子-β(TNF-β)在肿瘤组织与血浆中表达及其临床意义。方法收集97例不同类型淋巴瘤患者石蜡组织和血浆标本,应用免疫组化和ELISA法观察组织与血浆中TNF-β表达情况。结果 TNF-β在霍奇金淋巴瘤(HL)、弥漫大B细胞淋巴瘤(DLBCL)、浆细胞肿瘤(PCN)、小淋巴细胞淋巴瘤/慢性淋巴细胞白血病(SLL/CLL)、滤泡性淋巴瘤(FL)、周围T细胞淋巴瘤(PTL)表达较高,而在淋巴母细胞淋巴瘤(LBL)、结外NK/T细胞淋巴瘤(NK/TCL)表达较低,各种类型淋巴瘤组织TNF-β的表达情况比较,差异无统计学意义(P>0.05)。在HL、DLBCL、PCN、SLL/CLL、FL、PTL患者血浆中TNF-β水平高于健康对照组,差异有统计学意义(P<0.05)。组织中TNF-β表达在国际预后指标(IPI)评分的中、高危组与低危组比较,差异有统计学意义(P<0.05)。TNF-β在组织与血浆中的表达无相关性(rs=0.12,P>0.05)。结论 TNF-β在淋巴瘤组织与血浆中都有不同程度表达,提示TNF-β在淋巴瘤发生、发展中起到一定作用,但是TNF-β与淋巴瘤的关系比较复杂,不同的类型可能存在不同的机制。 Objective To investigate the expression of tumor necrosis factor β(TNF-β) in tissue and plasma of subtypes of lym- phoma and its significance. Methods Immunohistochemical technique and enzyme-linked immunosorbent assay(ELISA) were re- spectively used to assess the expression of TNF-β in 97 cases paraffin tissue and plasma samples of subtypes of lymphoma. Results Expressions of TNF-β were higher in HL, DLBCL, PCN, SLL/CLL, FL and PTL then in LBL, and NK/TCL. Expressions of TNF-β in tissue of subtypes of lymphoma had not significant difference(P〉0.05). Expression of TNF-β in plasma of HL,DLBCL, PCN, SLL/CLL,FL and PTL were higher than control group,TNF-β in these lymphoma were significant difference(P〈0.05). Ex- pressions of TNF-β in tissue had significant difference between low-risk group and middle or high risk group of international prog- nosis index(P〈0.05). Expressions of TNF-β in tissue and plasma of subtypes of lymphoma had no correlation(rs= 0. 12, P〉 0.05). Conclusion TNF-β has been found various degree expressions in tissue and plasma of lymphoma,TNF-β play a role in the development of lymphoma, but the expression of TNF-β in subtypes of lymphoma may exist different mechanisms.
出处 《重庆医学》 CAS CSCD 北大核心 2012年第18期1795-1798,F0002,共5页 Chongqing medicine
基金 国家自然科学基金支持项目(30860096)
关键词 淋巴瘤 肿瘤坏死因子类 组织 血浆 lyrnphoma tumor necrosis factors tissues plasma
  • 相关文献

参考文献16

  • 1赵洪云,钟雪云,陈运贤.肿瘤坏死因子基因多态性与非霍奇金淋巴瘤临床与预后的相关研究[J].中国肿瘤临床,2010,37(1):23-28. 被引量:2
  • 2Jaffy ES,Harris NL,Stein H,et al.World Health Organization classification of tumours pathology and genetics of tumours of haematopoietic and lymphoid tissues[M].Lyon:Iarc Press,2008:111-113.
  • 3顾霞,林汉良.不同类型淋巴瘤Survivin的表达及其意义[J].癌症,2004,23(6):655-661. 被引量:18
  • 4Mcdevitt H,Munson S,Ettinger R,et al.Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity[J].Arthritis Res,2002,4(3):141-152.
  • 5Christine F,Skibola,Paige M,et al.Tumor necrosis factor(TNF)and lymphotoxin-α(LTA)polymorphisms and risk of Non-Hodgkin lymphoma in the InterLymph consortium[J].Am J Epidemiol,2010,171(3):267-276.
  • 6Cerhan JR,Liu-Mares W,Fredericksen ZS,et al.Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin′s lymphoma[J].Cancer Epidemiol Biomarkers Prev,2008,17(11):3161-3169.
  • 7车坤兰,罗程,何凤仪,谭淑娴,曾改鸿,陈盛强.子宫内膜异位症与肿瘤坏死因子TNFα-308G/A和TNFβG252A基因多态性的关系[J].解剖学研究,2010,32(1):21-24. 被引量:4
  • 8赵洪云,陈运贤.肿瘤坏死因子基因多态性与血液系统恶性肿瘤[J].癌症,2003,22(2):216-220. 被引量:10
  • 9Saberi Hosnijeh F,Krop EJ,Scoccianti C,et al.Plasma cytokines and future risk of non-Hodgkin lymphoma(NHL):a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition[J].Cancer Epidemiol Biomarkers Prev,2010,19(6):1577-1584.
  • 10Sappino AP,Seelentag W,Pelte MF,et al.Tumor necrosis factor/cachectinand lymphotoxin gene express patients[J].Blood,1990,75(4):958-962.

二级参考文献94

  • 1顾霞,林汉良,沈艳,茹景顺,周伟,孙艺.不同类型淋巴瘤中survivin和bcl-2的表达及意义[J].临床与实验病理学杂志,2005,21(2):159-163. 被引量:11
  • 2罗敏,何援利,张宏斌,申东翔,宗利丽,关婷.广东妇女子宫内膜异位症与肿瘤坏死因子-β基因多态性的相关性研究[J].南方医科大学学报,2006,26(8):1163-1165. 被引量:3
  • 3罗敏,申东翔,张宏斌,宗利丽,关婷,何援利.子宫内膜异位症与肿瘤坏死因子-α基因多态性的相关性[J].广东医学,2006,27(10):1498-1499. 被引量:3
  • 4Salles G, Bienvenu J, Bastion Y, et al. Elevated circulating levels of TNF alpa and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients[J]. BrJ Haematol, 1996, 93(2): 352-359.
  • 5Warzocha K, Salles G, BienvenuJ, et al. The tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients[J]. J Clin Oncol, 1997, 15(2) : 499-508.
  • 6Gibbons DL, Rowe M, Cope AP, et al. Lymphotoxin acts as an autocrine growth factor for Epstein--Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines[J]. EurJ Immunol, 1994, 24(8): 1879-1885.
  • 7Maeda M, Watanabe N, Okamoto T, et al. Endogenous tumor necrosis factor functions as a resistant factor against adriamycin [J]. IntJ Cancer, 1994, 58(3): 376-379.
  • 8Juszczynski P, Kalinka E, BienvenuJ, et al. Human leukocyte anti- gens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome [J]. Blood, 2002, 100(8): 3037-3040.
  • 9Loparev VN, Cartas MA, Monken CE, et al. An efficient and simple method of DNA extraction from whole blood and cell lines to identify infectious agents[J].J Virol Methods, 1991, 34(1): 105--112.
  • 10Wilson AG, de Vries N, Pociot F, et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLAA1,B8 and DR3 alleles[J]. J Exp Med, 1993, 177(2): 557-560.

共引文献33

同被引文献11

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部